Cystic Fibrosis: New CF Research & Clinical Trials

Although most cystic fibrosis (CF) patients respond to new drug combinations which activate the proteins commonly affected by the disease, around 15% of patients are still without a treatment option. George Solomon, MD, discusses how UAB’s participation in the international “Path to a Cure” initiative will expand treatment options for all CF patients. He summarizes the three prongs of the path: developing a wider range of protein modulators, finding safe and ethical ways to administer genetic therapies, and ultimately finding a universal cure for CF. But what can we do now for CF patients with less common mutations? Learn more about how the UAB Medicine Cystic Fibrosis Program gives patients with tough-to-treat protein mutations access to emerging therapies through clinical trials.